Form 4 for URGN UroGen Pharma Ltd.
Accepted 2026-06-24 10:22:49 ET · period of report 2026-06-22 · accession 0001437749-26-021523 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2026-06-24 10:22 | 2026-06-22 | URGN | Schoenberg Mark | Chief Medical Off | S - Sale | $35.01 | -10.0K | 129.8K | -7% | -$350.1K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2026-06-22 | S | D | 10,000 | $35.01 | 129,763 | D | — | — | (F1) Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c). Adoption date of referenced 10b5-1(c) plan is: 08-15-2025. (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 and $35.08. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. |